Roche Holding AG (OTCMKTS:RHHBY) Given Average Recommendation of “Hold” by Brokerages

Roche Holding AG (OTCMKTS:RHHBY) has earned an average rating of “Hold” from the eleven brokerages that are currently covering the firm, Marketbeat reports. Six investment analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $51.50.

A number of brokerages have issued reports on RHHBY. Wolfe Research reissued an “outperform” rating on shares of Roche in a research note on Thursday, February 26th. Morgan Stanley raised shares of Roche from an “underweight” rating to an “equal weight” rating and set a $46.00 target price for the company in a research note on Friday, April 24th. TD Cowen reaffirmed a “hold” rating on shares of Roche in a research note on Tuesday, February 10th. Finally, Argus raised shares of Roche from a “hold” rating to a “buy” rating in a research note on Monday, April 6th.

Institutional Investors Weigh In On Roche

Several institutional investors and hedge funds have recently modified their holdings of the business. Curio Wealth LLC bought a new position in shares of Roche during the 3rd quarter worth about $25,000. McIlrath & Eck LLC bought a new position in shares of Roche during the 1st quarter worth about $39,000. Oakworth Capital Inc. increased its holdings in shares of Roche by 20.8% during the 4th quarter. Oakworth Capital Inc. now owns 1,658 shares of the company’s stock worth $86,000 after purchasing an additional 285 shares during the period. Atlas Capital Advisors Inc. bought a new position in shares of Roche during the 4th quarter worth about $192,000. Finally, Douglass Winthrop Advisors LLC bought a new position in shares of Roche during the 3rd quarter worth about $201,000.

Roche News Roundup

Here are the key news stories impacting Roche this week:

• Positive Sentiment: Roche entered a global collaboration with Nurix Therapeutics to co-develop and co-commercialize bexobrutideg, an investigational BTK degrader for blood cancers with potential expansion into immunology and neurology. The deal includes a $700 million upfront payment, a possible total value of up to $2.3 billion, and gives Roche another shot at strengthening its oncology pipeline. Article Title
• Positive Sentiment: The collaboration was also framed as a strategic fit with Roche’s existing B-cell therapy and commercialization capabilities, which could support future growth if bexobrutideg succeeds in clinical development. Article Title
• Neutral Sentiment: Roche said it is keeping its planned €600 million investment in Germany despite broader industry concerns and some competitors scaling back spending there. This supports its long-term manufacturing and European footprint, but the immediate stock impact is likely limited. Article Title
• Negative Sentiment: No major negative company-specific development was reported in the latest batch of news; however, investors may be watching execution risk around the large Nurix deal and the cost of continued pipeline investment. Article Title

Roche Trading Down 0.6%

Shares of OTCMKTS:RHHBY opened at $50.23 on Wednesday. The firm has a fifty day moving average of $50.97 and a two-hundred day moving average of $52.39. Roche has a 12-month low of $37.51 and a 12-month high of $60.85. The company has a debt-to-equity ratio of 0.72, a current ratio of 1.38 and a quick ratio of 1.12.

About Roche

Roche Holding AG is a Swiss multinational healthcare company headquartered in Basel, founded in 1896 by Fritz Hoffmann‑La Roche. The company operates primarily through two complementary divisions — Pharmaceuticals and Diagnostics — and is known for integrating drug development with diagnostic capabilities to advance personalized healthcare. In the United States and other international markets, shares trade as American Depositary Receipts under the ticker RHHBY (OTCMKTS:RHHBY).

In pharmaceuticals, Roche focuses on developing and commercializing prescription medicines across therapeutic areas including oncology, immunology, infectious diseases and neuroscience, with a notable emphasis on targeted biologics and personalized therapies.